Update date
03 Mar 2026
Cellebrite DI Ltd. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Public ticker
- CLBT on Nasdaq
- Latest financial report
- 03 Mar 2026
- Company location
- Petah Tikva, Israel
- Fiscal year end
- 31 December
Company
Names, identifiers, and filing context for this profile.
1 identity field
SEC filing record 1 source field available
Shareable Research Card
CLBT - Cellebrite DI Ltd. Financial Facts
CLBT - Cellebrite DI Ltd. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q1 2026
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q1 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q1 2026.
- Most recent SEC facts end date on this page: 23 Feb 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for CLBT - Cellebrite DI Ltd.
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q1 2026
SEC-backed company facts were refreshed from filings filed on 03 Mar 2026.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Key facts
- CLBT - Cellebrite DI Ltd. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric summary will appear when SEC facts are available.
Change
- No metrics are currently available for comparison on this facts page.
- Changes will populate automatically as new 10-Q/10-K periods are processed.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value above price
About fair
Medium confidence
3.8%
fair value gap
Fair value per share
$13.48
Market price
$12.99
CLBT - Local security
PEG ratio
0.3x
P/E 41.4x / growth 127%
Free Cash Flow CAGR (3Y)
Enterprise value
$3.24B
Equity value
$3.37B
DCF fair value scenarios
Bear
$10.18
- Growth
- 9%
- Discount
- 11%
- Terminal
- 2%
Gap -22%
Base
$13.48
- Growth
- 12%
- Discount
- 10%
- Terminal
- 2.5%
Gap 3.8%
Bull
$18.67
- Growth
- 15%
- Discount
- 9%
- Terminal
- 3%
Gap 44%
Base growth: Free Cash Flow CAGR (3Y).
Key valuation metrics
EV/Revenue
6.6x
Local security market EV / SEC revenue
EV/EBITDA
39.8x
Local security market EV / SEC EBITDA
P/E
41.4x
Local security market price / SEC EPS
P/S
6.8x
Local security market cap / SEC revenue
P/B
6.7x
Local security market cap / SEC equity
PEG
0.3x
P/E / Free Cash Flow CAGR
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $160.32M
- Trailing SEC FCF
- Reported FCF
- $160.32M
- Net income
- $78.33M
- EBITDA
- $78.35M
- Cash
- $124.46M
- Debt
- n/a
- Equity
- $484.32M
- Shares
- 249,903,126
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Debt missing: equity value treats debt as 0
- Dcf historical free cash flow growth is capped for scenario conservatism
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Financial Health
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 249,439,817 | +4.2% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
CIK / security context first